Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve

Gene Therapy

Volumn 21, Issue 6, 2014, Pages 549-557

  Hoyng, S A ^a,b   Gnavi, S ^a,c   De Winter, F ^a,b   Eggers, R ^a   Ozawa, T ^d   Zaldumbide, A ^b   Hoeben, R C ^b   Malessy, M J A ^a,b   Verhaagen, J ^a,e  

^a NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF TOKYO   (Japan)

^e VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; TETRACYCLINE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EX VIVO STUDY; EXPLANT; FEMALE; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; NONHUMAN; PERIPHERAL NERVE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; HEK293 CELL LINE; IMMUNOLOGY; IN VITRO STUDY; LENTIVIRINAE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHARMACOLOGY; PHYSIOLOGY; PROCEDURES; SKELETAL MUSCLE; WISTAR RAT; ANIMAL CELL; IMMUNOGENICITY; IN VIVO STUDY;

HUMAN HERPESVIRUS 4; RATTUS;

ANIMALS; BASE SEQUENCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; IN VITRO TECHNIQUES; LENTIVIRUS; MOLECULAR SEQUENCE DATA; MUSCLE, SKELETAL; PERIPHERAL NERVES; RATS, WISTAR; T-LYMPHOCYTES, CYTOTOXIC; TETRACYCLINE; TRANS-ACTIVATORS;

EID: 84902119815     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.22     Document Type: Article

References (45)

1. Mason MRJ, Tannemaat MR, Malessy MJA, Verhaagen J. Gene Ther.apy for theperipheral nervous system: a strategy to repair the injured nerve? Curr Gene Ther.2011; 11: 75-89.
2. Hoyng SA, Tannemaat MR, De Winter F, Verhaagen J, Malessy MJA. Nerve surgeryand gene Therapy: a nEur.obiological and clinical perspective. J Hand Surg Eur. Vol2011; 36: 735-746.
3. Li L, Wu W, Lin LF, Lei M, Oppenheim RW, Houenou LJ. Res.cue of adult mousemotonEurons from injury-induced cell death by glial cell line-derivedn Eurotrophic factor. Proc Natl Acad Sci USA 1995; 92: 9771-9775.
4. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M et al.GDNF: a potent survival factor for motonEur.ons pRes.ent in peripheral nerveand muscle. Science 1994; 266: 1062-1064.
5. Blits B, Carlstedt TP, Ruitenberg MJ, de Winter F, Hermens WTJMC, Dijkhuizen PAet al. Res.cue and sprouting of motonEur.ons following ventral root avulsion andreimplantation combined with intraspinal adeno-associated viral vector-Med.iatedexpRes.sion of glial cell line-derived nEur.otrophic factor or brain-derivednEur.otrophic factor. Exp NEur.ol 2004; 189: 303-316.
6. Eggers R, Hendriks WTJ, Tannemaat MR, van Heerikhuize JJ, Pool CW, Carlstedt TPet al. NEur.oregenerative effects of lentiviral vector-Med.iated GDNF expRes.sion inreimplanted ventral roots. Mol Cell NEur.osci 2008; 39: 105-117.
7. Tannemaat MR, Eggers R, Hendriks WT, De Ruiter GCW, Van Heerikhuize JJ, Pool CW et al. Differential effects of lentiviral vector-Med.iated overexpRes.sion ofnerve growth factor and glial cell line-derived nEur.otrophic factor on regeneratingsensory and motor axons in the transected peripheral nerve. Eur. J NEur.osci2008; 28: 1467-1479.
8. Gossen M, Bujard H. Tight control of gene expRes.sion in mammalian cells bytetracycline-Res.ponsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
9. Gossen M, Freundlieb S, Bender G, Müller G, Hillen W, Bujard H. Transcriptionalactivation by tetracyclines in mammalian cells. Science 1995; 268: 1766-1769.
10. Rivera VM, Clackson T, Natesan S, Pollock R, Amara JF, Keenan T et al.A humanized system for pharmacologic control of gene expRes.sion. Nat Med.1996; 2: 1028-1032.
11. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW.The mechanism of RU486 antagonism is dependent on the conformation of thecarboxy-terminal tail of the human progesterone receptor. Cell 1992; 69: 703-713.
12. Roscilli G, Rinaudo CD, Cimino M, Sporeno E, Lamartina S, Ciliberto G et al.Long-term and tight control of gene expRes.sion in mouse skeletal muscle by anew hybrid human transcription factor. Mol Ther. 2002; 6: 653-663.
13. Karns LR, Kisielewski A, Gulding KM, Seraj JM, TheodoRes.cu D. Manipulation ofgene expRes.sion by an ecdysone-inducible gene switch in tumor xenografts. BMCBiotechnol 2001; 1: 11.
14. Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. In vivo gene regulationusing tetracycline-regulatable systems. Adv Drug Deliv Rev. 2009; 61: 527-541.
15. Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W. Exploring thesequence space for tetracycline-dependent transcriptional activators: novelmutations yield expanded range and sensitivity. Proc Natl Acad Sci USA 2000; 97:7963-7968.
16. Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C. Regulateddelivery of glial cell line-derived nEur.otrophic factor into rat striatum, using atetracycline-dependent lentiviral vector. Hum Gene Ther.apy 2004; 15: 934-944.
17. Chtarto A, Yang X, Bockstael O, Melas C, Blum D, Lehtonen E et al. Controlleddelivery of glial cell line-derived nEur.otrophic factor by a single tetracyclineinducibleAAV vector. Exp NEur.ol 2007; 204: 387-399.
18. Yang X, Mertens B, Lehtonen E, Vercammen L, Bockstael O, Chtarto A et al.Reversible nEur.oChem.ical changes Med.iated by delayed intrastriatal glial cell linederivednEur.otrophic factor gene delivery in a partial Parkinson's diseaserat model. J Gene Med. 2009; 11: 899-912.
19. Chenuaud P, Larcher T, Rabinowitz JE, Provost N, Joussemet B, Bujard H et al.Optimal design of a single recombinant adeno-associated virus derived fromserotypes 1 and 2 to achieve more tightly regulated transgene expRes.sion fromnonhuman primate muscle. Mol Ther. 2004; 9: 410-418.
20. Latta-Mahieu M, Rolland M, Caillet C, Wang M, Kennel P, Mahfouz I et al. Genetransfer of a chimeric trans-activator is immunogenic and Res.ults in short-livedtransgene expRes.sion. Hum Gene Ther. 2002; 13: 1611-1620.
21. Favre D, Blouin V, Provost N, Spisek R, Porrot F, Bohl D et al. Lack of an immuneRes.ponse against the tetracycline-dependent transactivator correlates with longtermdoxycycline-regulated transgene expRes.sion in nonhuman primates afterintramuscular injection of recombinant adeno-associated virus. J Virol 2002; 76:11605-11611.
22. Zaldumbide A, Hoeben RC. How not to be seen: immune-evasion strategies ingene. Ther.apy. Gene Ther. 2008; 15: 239-246.
23. Horst D, Verweij MC, Davison AJ, Res.sing ME, Wiertz EJHJ. Viral evasion of T cellimmunity: ancient mechanisms offering new applications. Curr Opin Immunol2011; 23: 96-103.
24. Zaldumbide A, Weening S, Cramer SJ, MJWE Rabelink, Verhaagen J, Hoeben RC. Apotentially immunologically inert derivative of the Rev.erse tetracycline-controlledtransactivator. Biotechnol Lett 2010; 32: 749-754.
25. Ermak G, Cancasci VJ, Davies KJA. Cytotoxic effect of doxycycline and itsimplications for tet-on gene expRes.sion systems. Anal BioChem. 2003; 318:152-154.
26. Eggers R, de Winter F, Hoyng SA, Roet KCD, Ehlert EM, Malessy M et al. Lentiviralvector-Med.iated gradients of GDNF in the injured peripheral nerve: effects onnerve coil formation, Schwann cell maturation and myelinisation. PLoS One 2013;8: e71076.
27. Kanno A, Yamanaka Y, Hirano H, Umezawa Y, Ozawa T. Cyclic luciferase forreal-time sensing of caspase-3 activities in living mammals. Angew Chem.Int EdEngl 2007; 46: 7595-7599.
28. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev. Cancer 2004; 4:757-768.
29. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition ofubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeatdomain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997;94: 12616-12621.
30. Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A et al. Human CD8+ Tcell Res.ponses to EBV EBNA1: HLA class I pRes.entation of the (Gly-Ala)-containingprotein requiRes. exogenous processing. Immunity 1997; 7: 791-802.
31. Ossevoort M, Zaldumbide A, Cramer SJ, van der Voort EIH, Toes REM, Hoeben RC.Characterization of an immuno "stealth" derivative of the herpes simplex virusthymidine-kinase gene. Cancer Gene Ther. 2006; 13: 584-591.
32. Hendriks WTJ, Eggers R, Verhaagen J, Boer GJ. Gene transfer to the spinal cordnEur.al scar with lentiviral vectors: predominant transgene expRes.sion inastrocytes but not in meningeal cells. J NEur.osci Res. 2007; 85:3041-3052.
33. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G et al.Inhibition of antigen processing by the internal repeat region of the Epstein-Barrvirus nuclear antigen-1. Nature 1995; 375: 685-688.
34. Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L et al. Majorsource of antigenic peptides for the MHC class I pathway is produced during thepioneer round of mRNA translation. Proc Natl Acad Sci USA 2011; 108:11572-11577.
35. Apcher S, Komarova A, Daskalogianni C, Yin Y, Malbert-Colas L, Fåhraeus R.mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclearantigen 1. J Virol 2009; 83: 1289-1298.
36. Apcher S, Daskalogianni C, Manoury B, Fåhraeus R. Epstein Barr virus-encodedEBNA1 interference with MHC class I antigen pRes.entation Rev.eals a close correlationbetween mRNA translation initiation and antigen pRes.entation. PLoS Pathog2010; 6: e1001151.
37. Lu F, Wikramasinghe P, Norseen J, Tsai K, Wang P, Showe L et al. Genome-wideanalysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen1 (EBNA1). Virol J 2010; 7: 262.
38. DRes.ang LR, Vereide DT, Sugden B. Identifying sites bound by Epstein-Barr virusnuclear antigen 1 (EBNA1) in the human genome: defining a position-weightedmatrix to predict sites bound by EBNA1 in viral genomes. J Virol 2009; 83:2930-2940.
39. Zhou X, Vink M, Klaver B, Berkhout B, Das a T. Optimization of the Tet-On systemfor regulated gene expRes.sion through viral evolution. Gene Ther. 2006; 13:1382-1390.
40. Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Marzio G et al. Viral evolution as a toolto improve the tetracycline-regulated gene expRes.sion system. J Biol Chem. 2004;279: 18776-18782.
41. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME et al.Perspectives for the treatment of brucellosis in the 21st century: the Ioanninarecommendations. PLoS Med. 2007; 4: e317.
42. Hendriks WTJ, Eggers R, Carlstedt TP, Zaldumbide A, Tannemaat MR, Fallaux FJet al. Lentiviral vector-Med.iated reporter gene expRes.sion in avulsed spinal ventralroot is short-term, but is prolonged using an immune "stealth" transgene.Res.tor NEur.ol NEur.osci 2007; 25: 585-599.
43. Baron U, Bujard H. Tet repRes.sor-based system for regulated gene expRes.sion ineukaryotic cells: principles and advances. Methods Enzymol 2000; 327: 401-421.
44. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D et al. A third-generationlentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
45. Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo genedelivery and stable transduction of nondividing cells by a lentiviral vector. Science1996; 272: 263-267.